Abstract
The purpose of this study was to determine the relationship between platinum-DNA adducts in leukemic cells and the success of remission induction therapy in adult patients with acute nonlymphocytic leukemia (ANLL). Freshly isolated cells from pre-treatment bone marrow aspirates of 14 patients were incubated with cisplatin in vitro and the amount of platinum bound to DNA was determined using a competitive ELISA procedure and an antibody directed against platinum-modified DNA. Platinum-DNA adduct levels discriminated well between complete remission (CR) and remission failure (RF) patients, treated with mitoxantrone, cytosine arabinoside +/- carboplatin.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow / metabolism
-
Bone Marrow / pathology
-
Cisplatin / metabolism*
-
Cytarabine / administration & dosage
-
DNA Adducts / analysis*
-
DNA Adducts / metabolism
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / metabolism
-
Leukemia, Myeloid, Acute / pathology*
-
Male
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Organoplatinum Compounds / analysis*
-
Organoplatinum Compounds / metabolism
-
Predictive Value of Tests
-
Recurrence
-
Remission Induction
Substances
-
1,2-cyclohexanediamine platinum(II)-DNA complex
-
DNA Adducts
-
Organoplatinum Compounds
-
Cytarabine
-
Mitoxantrone
-
Cisplatin